| Autor: |
López, Irene Solana, Gutiérrez Abad, David, de Torres Olombrada, Maria Victoria, Martínez Moreno, Elia, Juez Martel, Ignacio, Hurtado Nuño, Alicia, Martín Fernández de Soignie, Ana Manuela, de Zea Luque, Carlos, Sánchez Baños, Nadia, Escalona Martín, Fátima, Losada Vila, Beatriz, Pantín González, Carmen, Lajusticia, Laura Rodríguez, Malón Giménez, Diego, Munarriz, Beatriz Jiménez, Hernández López, Roberto, Calzas Rodríguez, Julia, Guerra Martínez, Juan Antonio |
| Předmět: |
|
| Zdroj: |
Oncology in Clinical Practice (2450-1654); 2024, Vol. 20 Issue 5, p311-318, 8p |
| Abstrakt: |
Introduction. Gastric (GAD), gastroesophageal junction (GEJA), and esophageal adenocarcinoma (EAD) share pathophysiological features. At localized stages, FLOT is used perioperatively for the treatment of GAD and GEJA and CROSS for EAD and some GEJA. Although both therapies have been compared with MAGIC, comparative randomized data on FLOT and CROSS are not yet available. Material andmethods. We retrospectively analyzed and compared 40 patients treated with FLOT and 16 patients treated with CROSS in terms of clinical features and neoadjuvant, surgical, adjuvant, and survival outcomes. Results. At the time of analysis, 65% of patients treated with FLOT4 and 56.3% with CROSS remained in complete remission. Those who progressed after FLOT4 did so mainly at the peritoneal level (25%) and after CROSS at the bone, lymph node, and peritoneal levels (12.5% respectively). Six patients (37.5%) died after CROSS (median OS of 17.5 months; 95% CI 2-41) and 10 (25%) after FLOT4 (median OS 16.5 months; 95% CI 11-22). For the living patients, the median numbers of months from diagnosis to the follow-up cutoff date were 47.5 (95% CI 11-67) and 27 (95% CI 14-44) for CROSS and FLOT4, respectively. There were no significant differences in median OS estimated by Kaplan Meier analysis [FLOT4: 50 ± 4.6 months (95% CI 40.9-59.2); CROSS: 51.2 ± 7 months (95% CI 37.4-65.0; p = 0.79)]. Conclusions. Although we obtained lower pCR rates; TNM downstaging after neoadjuvant therapy, R0 rates, tolerance, PFS, and OS were similar in both groups and comparable with trial results. The adjuvant compliance rate was high with FLOT4. CROSS allows sequencing with nivolumab in PD-L1+ tumors. [ABSTRACT FROM AUTHOR] |
| Databáze: |
Complementary Index |
| Externí odkaz: |
|
